Compugen Ltd. (TLV:CGEN)
781.60
-12.40 (-1.56%)
Feb 20, 2025, 5:24 PM IDT
Compugen Revenue
Compugen had revenue of $17.13M USD in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $59.85M, up 698.03% year-over-year. In the year 2023, Compugen had annual revenue of $33.46M with 346.12% growth.
Revenue (ttm)
$59.85M
Revenue Growth
+698.03%
P/S Ratio
n/a
Revenue / Employee
$880.18K
Employees
68
Market Cap
670.22M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical Industries | 60.26B |
Danel (Adir Yeoshua) | 2.71B |
Kamada | 588.75M |
Bait Bakfar | 102.08M |
Novolog (Pharm-Up 1966) | 1.73B |
Ilex Medical | 982.96M |
BrainsWay | 143.60M |
SofWave Medical | 210.53M |
Compugen News
- 5 days ago - Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 - PRNewsWire
- 5 days ago - Compugen: Immuno-Oncology Innovator Poised For A Comeback - Seeking Alpha
- 19 days ago - Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 23 days ago - TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse - Benzinga
- 6 weeks ago - Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - PRNewsWire
- 2 months ago - Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus
- 3 months ago - Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies - PRNewsWire
- 3 months ago - Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus